Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I clinical study of ALLO-715 in combination with Nirogacestat in patients with relapsed and refractory multiple myeloma

Next Previous
Trial Profile

Phase I clinical study of ALLO-715 in combination with Nirogacestat in patients with relapsed and refractory multiple myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allo 715 (Primary) ; Nirogacestat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Allogene Therapeutics

Most Recent Events

  • 12 Apr 2021 According to an Allogene Therapeutics media release, first patient has been dosed in this trial.
  • 25 Feb 2021 Status changed from planning to recruiting, according to a SpringWorks Therapeutics media release.
  • 23 Dec 2020 According to an Allogene Therapeutics media release, the USA FDA has cleared the an Investigational New Drug (IND) application for this study. Enrollment in this study is expected in the first quarter of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top